Randomized, open phase II study of immunization with the recombinant MAGE-3 protein [GSK 1572932A; MAGE-A3 ASCI] combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Zastumotide (Primary) ; AS02; AS15
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 08 Dec 2015 Accrual to date is 2%, according to United Kingdom Clinical Research Network record.
- 08 Dec 2015 Last checked against the United Kingdom Clinical Research Network.
- 25 Jul 2013 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History